NCT03531372已完成不适用
Efficacy and Safety of Mipolixin® Compared to Poliprotect ® in the Relief of Symptoms of Moderate Functional Dyspepsia and Heartburn: A Randomized, Double-blind, Parallel Group,Non-inferiority Clinical Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 158
- 试验地点
- 22
- 主要终点
- Change in overall symptom severity from baseline (day 0) to day 14 between the two study arms
研究概览
简要总结
Evaluation of the clinical efficacy of two medical devices, Mipolixin® and Poliprotect®, in improving the overall symptom severity of functional dyspesia and/or heartburn
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide informed consent, preferably in writing or, failing that, orally in front of a witness, before any study procedure is performed.
- •Male and female patients aged 18 to 75 years old (inclusive).
- •Patients with symptoms of functional dyspepsia (according to the Rome IV criteria) of moderate severity (VAS score between 30 mm and 70 mm) and/or bothersome heartburn within 2 and 14 days prior to the screening/baseline visit.
- •o According to the current Rome IV diagnostic criteria, functional dyspepsia is defined as one or more of the following symptoms: postprandial fullness (classified as postprandial distress syndrome), early satiation (inability to finish a normal sized meal, also classified as postprandial distress syndrome), and epigastric pain or burning (classified as epigastric pain syndrome).
- •Ability of the patients (according to the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.
- •Patients who agree not to alter their diet in any way for the duration of the trial and to maintain it at steady state.
- •Patients who agree not to make any major lifestyle changes during the trial.
- •Willingness to comply with all the study procedures and schedule.
- •Chronic therapies (if not related to the gastroenterological pathologies object of the study, according to the opinion of the investigator) are allowed, if the regimen is maintained stable during the whole study.
排除标准
- •Declines or unable to provide informed consent.
- •Disease or health condition
- •Patient presenting at least one of the following symptoms or conditions at screening: anemia, chronic gastrointestinal bleeding, progressive unintentional weight loss, epigastric mass, anorexia, persistent or recurrent vomiting, dysphagia or odynophagia, porphyria, hypophosphatemia, and/or cachexia.
- •Patients presenting with at least of the following gastrointestinal conditions at screening: erosive GERD, Barrett's oesophagus or oesophageal stricture, active or healing gastroduodenal ulcer (except scars), history of gastric, duodenal or esophageal surgery, symptomatic gallstone, and/or other gastrointestinal disease such as gastroenteritis, inflammatory bowel disease, celiac disease and/or colorectal cancer.
- •Patients with known malignancy disease, infectious disease or severe heart or pulmonary disease.
- •Patients with known severe liver or kidney disease (AST/SGOT, ALT/SGPT >2 upper limits of normal, serum creatinine >1.5 mg/dl).
- •Patients with mental or metabolic disorders and any other disease that according to the physician can compromise the patient´s safety and/or patient´s study compliance.
- •Treatments
- •Patients receiving any treatment (pharmacological or medical device) for heartburn or dyspeptic symptoms within the last 14 days prior to randomization.
- •Patients receiving any drugs that could affect symptoms or study evaluation such antacids, PPIs, H2RAs, prokinetics, and/or gastric mucosal protectants at baseline and/or taken within the last 14 days prior to randomization.
- •Patients receiving any drugs that could affect symptoms or the study as antibiotics, NSAIDs, anticholinergics and/or cholinergic agents.
- •Note: Patients will be asked to avoid any drugs of the above mentioned since the beginning of the study (baseline visit) until the end of the study.
- •Patients under triple therapy or eradication therapy against Helicobacter pylori.
- •Patients planned for long-term new therapies with anti-anxiety agents, glucocorticosteroids and anti-inflammatory agents during study period.
- •Known hypersensitive or intolerance to any components of the study medical devices.
- •Previous intake of any of the study medical devices.
- •Other general conditions
- •Patients who are unable to understand or are unwilling to sign an informed consent form.
- •Unable or unwilling to complete all required screening and/or follow-up assessments.
- •Unable to understand and complete self-administered scales/questionnaires planned to be used in the study.
- •Participation in interventional research studies of investigational medicinal or device products (ongoing or terminated less than 30 days before screening)
- •Patients with active alcohol or drug addiction or any other condition that, in the investigator's opinion, would interfere with their ability to comply with the study requirements.
- •Patients with any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
- •Pregnant or nursing (lactating) women;
- •Women of childbearing potential and sexually active: they must be willing to use at least one acceptable effective contraceptive measure (- progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action , - male or female condom with or without spermicide, - cap, diaphragm or sponge with spermicide). Pregnancy test will be performed at screening and at the final/premature withdrawal visit. The use of contraception in male patients is not required.
结局指标
主要结局
Change in overall symptom severity from baseline (day 0) to day 14 between the two study arms
时间窗: Day 0 and Day 14
The primary endpoint is the change in the score of a visual analog scale (VAS) (from "no symptoms" to "overwhelming symptoms") used for evaluating overall symptom severity from baseline (day 0) to day 14 after treatment initiation, between the two study arms. A decrease in VAS score of at least 30% is considered as a clinically meaningful improvement, and therefore subjects achieving a decrease ≥30% in this scale will be considered as responders. The non-inferiority is considered demonstrated if the 95% confidence interval of the difference in the percentage of responders between both study arms lies within the non-inferior margin value defined of 20%.
次要结局
- Self-assessment severity of individual specific symtoms(Day 0, Day 1, Day 3, Day 7 and Day 14)
- Patient satisfaction (taste)(Day 3, Day 7 and Day 14)
- Responders from baseline to day 3 and day 7(Day 0, Day 3 and Day 7)
- Change in the score of GOS scale from baseline to day 1(Day 0 and Day 14)
- Incidence of AEs and clinical findings during study period(Day 0 to Day 28)
- Incidence of AEs during study treatment(Day 0 to Day 14)
- Patient satisfaction (treatment administration)(Day 3, Day 7 and Day 14)
- Treatment compliance(Day 0 to Day 14)
研究者
研究点 (22)
Loading locations...
相似试验
Unknown
1 期
Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic PatientsPresbyopiaNCT05001243Optall Vision11
已完成
不适用
Thyroid Treatment TrialGraves OphthalmopathyNCT00348413Singapore National Eye Centre80
已完成
不适用
Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced VasospasmCerebral VasospasmSubarachnoid HemorrhageNCT03517670Nantes University Hospital60
已完成
不适用
Comparison of Remogliflozin with vildagliptin in the treatment of diabetesCTRI/2020/02/023120Maulana azad medical college
Unknown
4 期
Regional Anesthesia in Total Hip and Knee ArthroplastyKnee OsteoarthritisHip OsteoarthritisNCT04257682Ottawa Hospital Research Institute135